Objective To determine the association between direct oral anticoagulant (DOAC) use and
risk of major adverse cardiac events (MACEs) in patients with atrial fibrillation (AF). Patients …

Abstract Background Direct oral anticoagulants (DOACs) have been proven to be effective
and safe for prevention of ischemic stroke and systemic embolism in patients with non …

Objective To establish the risk of major bleeding in direct oral anticoagulant (DOAC) users
(overall and by class) versus vitamin K antagonist (VKA) users, using health care databases …

Direct Oral Anticoagulants (DOACs) require dose adjustment based on specific patient
characteristics, making them prone to incorrect dosing. The current study aimed to evaluate …

Background Direct oral anticoagulants (DOAC s) are noninferior to warfarin for stroke
prevention in atrial fibrillation (AF). We aimed to determine the population risk of stroke and …

Background: Oral anticoagulation (OAC) with warfarin is underused for atrial fibrillation (AF).
The availability of direct oral anticoagulants (DOACs) may improve overall OAC rates in AF …

The objective of the study was to examine how the comparative effectiveness and safety of
direct oral anticoagulants (DOACs) and warfarin differ across subgroups of patients with …

Background Clinical trials have demonstrated that direct oral anticoagulants (DOACs) are at
least non-inferior to warfarin in reducing the risk of stroke/systemic embolism (SE) among …

Background Although controversial, several prior studies have suggested that oral
anticoagulants (OACs) are underused in the US atrial fibrillation (AF) population …

Background Several observational studies have shown that the inappropriate dosing use of
direct oral anticoagulants (DOACs) in atrial fibrillation (AF) that does not conform to …